← Back to Search
Mesothelin-family Proteins And Diagnosis Of Mesothelioma
B. Robinson, J. Creaney, Richard Lake, A. Nowak, I. Hellstrom
Published 2003 · Medicine
Download PDFAnalyze on Scholarcy
BACKGROUND Mesothelioma is a highly aggressive tumour for which there are no reliable serum tumour markers. Identification of such a marker would be useful in diagnosis of mesothelioma and for monitoring responses to treatment and screening at-risk individuals. METHODS We assayed serum concentrations of soluble mesothelin-related proteins (SMR) using a double determinant (sandwich) ELISA in a blinded study of serum samples from 44 patients with histologically proven mesothelioma; 68 matched healthy controls, 40 of whom had been exposed to asbestos; and 160 patients with other inflammatory or malignant lung and pleural diseases. FINDINGS 37 (84%) of 44 patients with mesothelioma had raised concentrations of SMR at a serum dilution of 1/80, compared with three (2%) of 160 patients with other cancers or other inflammatory lung or pleural diseases, and with none of 28 controls who had not been exposed to asbestos. SMR concentrations correlated with tumour size and increased during tumour progression. Seven of the 40 asbestos-exposed individuals had increased serum concentrations of SMR; three of those seven developed mesothelioma and one developed lung carcinoma within 1-5 years. None of the 33 asbestos-exposed participants whose serum samples had normal concentrations of SMR and who were followed up over 8 years developed mesothelioma. INTERPRETATION Determination of SMR in serum could be a useful marker for diagnosis of mesothelioma and to monitor disease progression. It might also prove helpful for screening asbestos-exposed individuals for early evidence of mesothelioma.
This paper references
New chemotherapeutics in malignant mesothelioma: effects on cell growth and IL-6 production
B. McLaren (2000)
Clinical applications of serum tumor markers.
S. Bates (1991)
18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study.
A. Carretta (2000)
The role of tumor markers in gynecologic oncology.
G. Olt (1990)
Appropriateness of prostate-specific antigen testing.
H. Poteat (2000)
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M. Byrne (1999)
Malignant pleural mesothelioma.
L. Ho (2001)
Molecular Cloning and Expression of Megakaryocyte Potentiating Factor cDNA (*)
T. Kojima (1995)
Hyaluronan in pleural effusions and in serum
G. Hillerdal (1991)
Development of new therapeutic strategies for mesothelioma
B. W. Robinson (1993)
Multimodality treatment of diffuse malignant pleural mesothelioma.
L. Zellos (2002)
Structure of the Mesothelin/MPF gene and characterization of its promoter.
D. Urwin (2000)
New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents.
A. Nowak (2002)
A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5.
N. Yamaguchi (1994)
Vitamin A and cancer prevention I: Observations in workers previously exposed to asbestos at Wittenoom, Western Australia
A. Musk (1998)
Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE).
P. Argani (2001)
Immunopathology Of Lung Disease
R. Kradin (1996)
Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review.
D. Henderson (1998)
Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985.
K. Antman (1988)
Generating longitudinal screening algorithms using novel biomarkers for disease.
M. McIntosh (2002)
Molecular cloning and expression of a cDNA encoding a protein detected by the ki antibody from an ovarian carcinoma (OVCAR‐3) cell line
K. Chang (1994)
Management of recurrent colorectal cancer: another look at carcinoembryonic antigen-detected recurrence.
J. Vauthey (1996)
Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium.
K. Chang (1992)
Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma.
N. Scholler (1999)
Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity.
P. S. Chowdhury (1998)
Tumor-Specific CD4+ T Cells Have a Major “Post-Licensing” Role in CTL Mediated Anti-Tumor Immunity1
A. Marzo (2000)
Textbook of Lung Cancer
H. Hansen (1999)
The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma.
P. Johnson (2001)
Malignant pleural mesothelioma.
C. Boutin (1998)
Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically.
V. Rusch (1999)
Cytokine gene therapy of mesothelioma. Immune and antitumor effects of transfected interleukin-12.
Irina Caminschi (1999)
This paper is referenced by
Clinical Significance of Serum Mesothelin in Patients with Mesothelioma and Lung Cancer
A. Cristaudo (2007)
Assessment of biomarkers in asbestos-exposed workers as indicators of cancer risk.
M. Amati (2008)
A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes
M. Carbone (2007)
Clinical diagnosis and basic evaluation
John J. Mullon (2008)
Screening Issues in Exposed Subjects and Early Diagnosis
M. Mencoboni (2019)
Biomarkers for Early Detection of Malignant Mesothelioma: Diagnostic and Therapeutic Application
M. Tomasetti (2010)
Management of malignant pleural mesothelioma
P. Hürmüz (2010)
The Potential of BORIS Detected in the Leukocytes of Breast Cancer Patients as an Early Marker of Tumorigenesis
V. D'Arcy (2006)
Recent Advances in Surgical Techniques for Multimodality Treatment of Malignant Pleural Mesothelioma
C. Asteriou (2013)
Occupational toxicology of asbestos-related malignancies
M. Lotti (2010)
Chemokine (C-C motif) ligand 3 detection in the serum of persons exposed to asbestos: A patient-based study
J. Xu (2015)
Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic
O. D. Røe (2015)
Mesothelin-targeted immunotherapies for malignant pleural mesothelioma.
Jonathan Villena-Vargas (2012)
Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma: Ten Years of Clinical Experience in Relation to International Guidelines.
A. Hjerpe (2018)
Amatuximab and novel agents targeting mesothelin for solid tumors
P. Baldo (2017)
2.ラットERC/Mesothelin ELISA測定系の構築と腹水癌細胞移植Nude Mouse体液での測定
良明 萩原 (2007)
Pleural Biopsy for a Definitive Diagnosis of Malignant Pleural Mesothelioma
T. Mimura (2010)
Use of Yeast-Secreted In vivo Biotinylated Recombinant Antibodies (Biobodies) in Bead-Based ELISA
N. Scholler (2008)
Predictive Biomarkers and Personalized Medicine CD 26 Overexpression Is Associated with Prolonged Survival and Enhanced Chemosensitivity in Malignant Pleural Mesothelioma
K. Aoe (2012)
The diagnostic potential and biological significance of MicroRNA in Malignant Pleural Mesothelioma
Kimberly A. Birnie (2016)
Soluble mesothelin-related peptides (SMRP) - high stability of a potential tumor marker for mesothelioma.
D. Weber (2007)
Sensitive and Specific New Enzyme-Linked Immunosorbent Assay for N-ERC/Mesothelin Increases its Potential as a Useful Serum Tumor Marker for Mesothelioma
K. Shiomi (2008)
MESOTHELIOMA - A RARE CAUSE OF DYSPHAGIA
S. Vishwanathan (2016)
Utility of mesothelin, L1CAM and Afamin as biomarkers in primary ovarian cancer.
B. Aktas (2013)
Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?
J. Creaney (2011)
Does CA125 binding to mesothelin impact the detection of malignant mesothelioma?
J. Creaney (2013)
Sensitive and Specific New Enzyme-Linked Immunosorbent Assay for NERC / Mesothelin Increases its Potential as a Useful Serum TumorMarker for Mesothelioma
K. Shiomi (2008)
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
Asbestos-related pleural disease
R. Myers (2012)
An Update on Biomarkers and Treatment
Mandira Ray (2015)
Gene therapy for malignant mesothelioma: beyond the infant years
R. Most (2006)
Serum osteopontin levels--is it time to screen asbestos-exposed workers for pleural mesothelioma?
M. Cullen (2005)See more